Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan - JSH-MPN-15

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024340

Enrollment

1500

Registered

2016-10-13

Start date

2016-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MPN(myeloproliferative neoplasms)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients fulfilling the following criteria (1) Newly diagnosed patients fulfilling the 2016 WHO diagnostic criteria for MPN (2) Patients who have undergone a bone marrow biopsy with a presentable pathology report (3) Confirmed absence of either the Ph1 chromosome or BCR-ABL fusion gene (4) Patients in which informed consent was obtainable (5) Patients who were 16 years or older at the time of consent

Exclusion criteria

Exclusion criteria: Patients in which exclusion of MDS was not possible due to confirmation of myeloid or erythroid lineage morphological abnormalities on the bone marrow smear preparation

Design outcomes

Primary

Measure	Time frame
Investigation of overall survival of MPN (PV,ET,prePMF,PMF) patients in Japan.	—

Secondary

Measure	Time frame
Investigation of thrombotic and hemorrhagic events, transition rates and associated risk factors of transition to leukemia, secondary myelofibrosis and polycythemia vera -thrombotic and hemorrhagic events -transition to leukemia -transition to secondary myelofibrosis -transition to polycythemia vera -secondary malignancies -MPN-SAF TSS (Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score)	—

Measure

Time frame

Investigation of thrombotic and hemorrhagic events, transition rates and associated risk factors of transition to leukemia, secondary myelofibrosis and polycythemia vera -thrombotic and hemorrhagic events -transition to leukemia -transition to secondary myelofibrosis -transition to polycythemia vera -secondary malignancies -MPN-SAF TSS (Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score)

—

Countries

Japan

Contacts

Public ContactKatsuto Takenaka

Kyushu University Hospital Hematology and Oncology

takenaka@intmed1.med.kyushu-u.ac.jp092-641-1151

Outcome results